#USA #New York #Segmed #Precision Oncology #Nucs AI

Building a New Era in Precision Oncology: Nucs AI and Segmed Partnership

In a significant move for the field of oncology, Nucs AI has announced a strategic partnership with Segmed, a leader in real-world clinical and imaging data. This collaboration aims to harness powerful AI capabilities combined with extensive real-world data to enhance precision medicine in cancer treatment.

Understanding Precision Medicine

Precision medicine represents a transformative approach in healthcare, tailoring treatment methods to each patient based on their unique characteristics. With the complexity of diseases like cancer, understanding which therapies will benefit individual patients is crucial. A pivotal study known as the VISION trial illustrated this challenge; it revealed that over 50% of patients treated with lutetium-177 PSMA therapy did not see a positive change in their PSA levels. Such statistics underline the necessity for precise predictions based on broad data sets.

The Power of Partnership

The core component of this partnership lies in the fusion of Segmed's extensive and diversified data bank with Nucs AI's cutting-edge predictive modeling. Segmed’s library, encompassing information from over 2,800 healthcare providers and 150 million imaging studies, is a cornerstone in this initiative. Their lasting commitment to data diversity is pivotal; models developed from narrow or single-site data often reflect only specific contexts, limiting their application across various settings.

Through this collaboration, Nucs AI will gain access to rich, de-identified imaging and clinical data that spans a multitude of institutions, geographical locations, cancer types, and treatment modalities. This access will facilitate the development of next-generation predictive biomarkers, clinical intelligence solutions, and disease-specific registries that are vital for real-world evidence generation.

Addressing Data Bottlenecks

According to Nijat Ahmadov, CEO of Nucs AI, the major obstacles in precision medicine are centered around data, not models. To capitalize on the full accuracy and specificity that imaging data can provide, it’s essential to train on wider datasets that connect imaging with comprehensive clinical outcomes. By focusing on diverse datasets, the partnership is poised to solve data bottlenecks, allowing the exploration of pressing clinical questions without being limited to clean datasets.

With the inclusion of Segmed's expansive data resources, Nucs AI is prepared for rapid scaling. Their existing models have already utilized over 72,000 lesions for development purposes, and analysts expect that broader access will enhance capabilities across different cancer types, imaging modalities, and clinical scenarios.

Future Prospects

Both companies acknowledge the critical journey ahead. Jie Wu, Segmed’s Co-founder and Chief Data Officer, emphasizes that finding the right partners to leverage their vast data has always been the next step in advancing precision oncology. This partnership represents the kind of synergy that the industry needs to realize the full potential of available data.

In a bid to share insights and educate the healthcare community, Nucs AI and Segmed plan to hold a joint webinar on July 14, which is part of Segmed’s innovative series focused on health technologies.

As Nucs AI and Segmed embark on this collaborative venture, the future of precision oncology looks promising. By building stronger data foundations that seamlessly integrate imaging, clinical data, and treatment outcomes, they are set to revolutionize how therapies are delivered, ensuring that patients receive the most effective treatments tailored to their specific needs.

For more information on Nucs AI, visit Nucs AI. And for insights on Segmed, explore their offerings at Segmed.